Profile

CanaQuest is a clinical-stage life sciences company developing innovative cannabinoid-based therapeutics. Its primary focus, CQ-001, combines cannabidiol (CBD) with Omega-3 fatty acids to treat refractory epilepsy in 30%-40% of the 65 million affected people worldwide. This drug enhances binding to critical PPAR receptors in the brain, showing a 35% increase in potency over isolated CBD in pre-clinical models. Its expertise with FDA-approved cannabidiol (Epidiolex®) positions CanaQuest at the forefront of epilepsy treatment innovation.

CanaQuest logo

Website

canaquest.com

Contact


Event details

Date: September 25 - 27, 2024

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

13 in total